Drug Trial Radar · NCT00920582
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Dec 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
254
Actual
Start
Sep 2009
Primary completion
Apr 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Jun 15, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients recently diagnosed with type 1 diabetes.
Conditions
- Type 1 Diabetes Mellitus
Interventions
Teplizumab Herold RegimenBiological
Full dose of teplizumab IV for 14 days, repeated at Week 26
PlaceboDrug
IV dosing daily for 14 days repeated at Week 26
Teplizumab 33.3% Herold RegimenBiological
One third full dose of teplizumab IV for 14 days, repeated at Week 26
Teplizumab Curtailed Herold RegimenBiological
Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.Time frame: 52 weeks after randomization
- Mean Change From Baseline in HbA1c Between Teplizumab and PlaceboTime frame: 52 weeks after randomization
Locations
118 sites in 16 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
NEA Clinic
Jonesboro, Arkansas
Arkansas Children's Hospital
Little Rock, Arkansas
Clinical Innovations Inc. Research Facility
Costa Mesa, California
Axis Clinical Trials
Los Angeles, California
Diabetes Associates Medical Group, Inc
Orange, California
Clinical Innovations, Inc.
Riverside, California
San Diego Clinical Trials
San Diego, California
Ronald Chochinov Md Inc
Ventura, California
Yale University
New Haven, Connecticut
Christiana Care Research Institute
Newark, Delaware
Richard Hays, MD
Wellington, Florida
Atlanta Diabetes Associates
Atlanta, Georgia
John H Stoger Jr. Hospital of Cook County, Cook County Hospital
Chicago, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
University of Iowa Children's Hospital
Iowa City, Iowa
Mid-America Diabetes Associates
Wichita, Kansas
St. Agnes Hospital
Baltimore, Maryland
Maryland Diabetes & Endocrine Associates
Rockville, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Alzohaili Medical Consultants
Dearborn, Michigan
Children's Hospitals and Clinics of Minnesota
Saint Paul, Minnesota
University of Missouri - Columbia, Cosmopolitan Diabetes and Endocrinology
Columbia, Missouri
The Children's Mercy Hospital
Kansas City, Missouri
Saint Barnabas Medical Center
Livingston, New Jersey
Albany Medical College
Albany, New York
Bassett Healthcare
Cooperstown, New York
East Carolina University, Brody School of Medicine
Greenville, North Carolina
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
GHS Pediatric Endocrinology
Greenville, South Carolina
AM Diabetes & Endocrinology Center
Bartlett, Tennessee
University Diabetes & Endocrine Consultants
Chattanooga, Tennessee
LeBonheur Children's Medical Center
Memphis, Tennessee
Research Institute of Dallas
Dallas, Texas
Southwest Clinical Trials
Houston, Texas
Houston Center for Clinical Research
Houston, Texas
Medical & Surgical Clinic of Irving
Irving, Texas
InVisions Consultants, LLC
San Antonio, Texas
Diabetes and Glandular Disease Research Associates, PA
San Antonio, Texas
Endocrine Research Specialists
Ogden, Utah
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.